scholarly journals Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

Viruses ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 44
Author(s):  
Qiong Zhou ◽  
Michael R. MacArthur ◽  
Xinliang He ◽  
Xiaoshan Wei ◽  
Payam Zarin ◽  
...  
Keyword(s):  
Lung Disease ◽  
Study Cohort ◽  
C Reactive Protein ◽  
Clinical Predictors ◽  
Upper Airways ◽  
Reactive Protein ◽  
Immune Parameters ◽  
Lung Abnormalities ◽  
Ifn Treatment ◽  
Circulating Levels

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (COVID-19), a lung disease that may progress to systemic organ involvement and in some cases, death. The identification of the earliest predictors of progressive lung disease would allow for therapeutic intervention in those cases. In an earlier clinical study, individuals with moderate COVID-19 were treated with either arbidol (ARB) or inhaled interferon (IFN)-α2b +/−ARB. IFN treatment resulted in accelerated viral clearance from the upper airways and in a reduction in the circulating levels of the inflammatory biomarkers IL-6 and C-reactive protein (CRP). We have extended the analysis of this study cohort to determine whether IFN treatment had a direct effect on virus-induced lung abnormalities and also to ascertain whether any clinical or immune parameters are associated with worsening of lung abnormalities. Evidence is provided that IFN-α2b treatment limits the development of lung abnormalities associated with COVID-19, as assessed by CT images. Clinical predictors associated with worsening of lung abnormalities include low CD8+ T cell numbers, low levels of circulating albumin, high numbers of platelets, and higher levels of circulating interleukin (IL)-10, IL-6, and C-reactive protein (CRP). Notably, in this study cohort, IFN treatment resulted in a higher percentage of CD8+ T cells, lower tumor necrosis factor (TNF)-α levels and, as reported earlier, lower IL-6 levels. Independent of treatment, age and circulating levels of albumin and CRP emerged as the strongest predictors of the severity of lung abnormalities.

scholarly journals Dynamics of clinical, functional, and immune parameters in patients with myocardial infarction and early fluvastatin administration

2011 ◽  
Vol 10 (4) ◽  
pp. 52-58
Author(s):  
V. V. Belov ◽  
S. Yu. Bezdol’nova ◽  
I. I. Dolgushin
Keyword(s):  
Myocardial Infarction ◽  
Systemic Inflammation ◽  
Immunoglobulin A ◽  
Healthy Controls ◽  
C Reactive Protein ◽  
Complement Components ◽  
Reactive Protein ◽  
Immune Parameters ◽  
Factor Α ◽  
Necrosis Factor

Aim. To assess the interrelations in the dynamics of immune, clinical, and functional parameters among patients with myocardial infarction (MI) and early fluvastatin administration. Material and methods. The study included 129 men, aged from 42 to 67 years (mean age 57 years): 99 MI patients and 30 healthy controls. In all participants, clinical, biochemical, functional, and immune parameters were assessed, with comparisons between healthy individuals vs. MI patients, as well as between MI patients taking fluvastatin (80 mg/d) vs. MI patients not receiving this medication. Results. In men with MI, chronic systemic inflammation was manifested in elevated levels of C-reactive protein, interleukin (IL) 1β, IL8, tumor necrosis factor α, immunoglobulin A and G, and complement components, as well as in decreased levels of IL1 receptor antagonist, CD 3, CD 4, CD 16, and CD 4/CD 8, compared to healthy controls. Early fluvastatin administration (first post-MI hours) was associated with reduced severity of immune disturbances and systemic inflammation. Conclusion. In MI patients, early fluvastatin administration is associated with a significant reduction in systolic and diastolic blood pressure levels, compared to controls, as well as with a substantial increase in exercise capacity at 2 months.

scholarly journals Association Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity

Hypertension ◽  
2009 ◽  
Vol 53 (2) ◽  
pp. 150-157 ◽  
Author(s):  
Wiebke Schumacher ◽  
John Cockcroft ◽  
Nicholas J. Timpson ◽  
Carmel M. McEniery ◽  
John Gallacher ◽  
...  
Keyword(s):  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Aortic Pulse Wave Velocity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Circulating Levels ◽  
Protein Genotype

scholarly journals Anti-HLA Class II Antibodies Correlate with C-Reactive Protein Levels in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease

Cells ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 691
Author(s):  
Alma D. Del Angel-Pablo ◽  
Ivette Buendía-Roldán ◽  
Mayra Mejía ◽  
Gloria Pérez-Rubio ◽  
Karol J. Nava-Quiroz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Class Ii ◽  
Hla Class Ii ◽  
C Reactive Protein ◽  
Hla Antibodies ◽  
Protein Levels ◽  
Reactive Protein ◽  
Genetic And Environmental Factors

The pathogenesis of Rheumatoid Arthritis (RA) is not fully understood, probably influenced by genetic and environmental factors. Interstitial Lung Disease (ILD) is an extra-articular manifestation of RA, which contributes significantly to morbidity and mortality. The identification of anti-HLA antibodies has been useful in the transplantation field; however, its contribution to autoimmune diseases as RA has not been fully studied. We aimed to determine the presence of anti-HLA antibodies in RA patients with and without ILD and its possible association with clinical and biochemical markers. One-hundred and forty-seven RA patients, of which 65 had ILD (RA-ILD group), were included. Sera samples for Anti-HLA Class II LABScreen panel-reactive antibodies (PRA) were analyzed. In both groups, women predominated, and lung function was worse in patients with ILD. The anti-CCP+ (UI/mL) was higher in the RA group in comparison to RA-ILD (p < 0.001). Expositional risk factors (tobacco smoking and biomass-burning smoke) were higher in RA-ILD patients. PRA+ was identified in ~25% RA-ILD patients, while ~29% in the RA group. The CRP levels have a positive correlation with the percentage of reactivity (%PRA, p = 0.02, r2 = 0.60) in the RA-ILD group. In conclusion, anti-HLA antibodies correlate with C-reactive protein levels in RA patients with ILD.

Myocardial interleukin-6 in the setting of left ventricular mechanical assistance: relation with outcome and C-reactive protein

2015 ◽  
Vol 53 (9) ◽  
Author(s):  
Raffaele Caruso ◽  
Chiara Caselli ◽  
Lorena Cozzi ◽  
Jonica Campolo ◽  
Federica Viglione ◽  
...  
Keyword(s):  
Left Ventricular ◽  
Circulatory Support ◽  
C Reactive Protein ◽  
Tissue Samples ◽  
Ventricular Assist ◽  
Reactive Protein ◽  
Left Ventricular Assist ◽  
Serum Crp ◽  
Circulating Levels ◽  
Post Implantation

AbstractIn left ventricular assist device (LVAD) recipients, plasma levels of interleukin (IL)-6 are associated with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles, reflecting post-operative risk. However, it is not clear how the cardiac level of IL-6, detectable on the tissue samples at the time of implantation, can contribute to predict the post-operative outcome.In 40 LVAD recipients, blood and myocardial samples from LV-apex were collected at the time of implantation to assess plasma and cardiac IL-6 levels. Serum C-reactive protein (CRP) levels were considered as inflammatory variable routinely used in LVAD-based therapy.Cardiac IL-6 levels did not correlate with either plasma IL-6 levels (R=0.296, p=0.063) and tissue IL-6 mRNA expression (R=–0.013, p=0.954). Contrary to what happened for the plasma IL-6 and CRP, no differences were observed in cardiac IL-6 levels with respect to INTERMACS profiles (p=0.090). Furthermore, cardiac IL-6 concentrations, unlike IL-6 and CRP circulating levels, were not correlated with the length of intensive care unit stay and hospitalization.Cardiac IL-6 levels do not contribute to improve risk profile of LVAD recipients in relation to clinical inpatient post-implantation. Instead, plasma IL-6 and serum CRP concentrations are more effective in predicting the severity of the clinical course in the early phase of LVAD therapy.

Association between Body Weight and Telomere Length is Predominantly Mediated through C-Reactive Protein

2021 ◽  
Author(s):  
Xiao Gao ◽  
Shengxu Li ◽  
Shiqiu Dong ◽  
Jiaqi Li ◽  
Yinkun Yan ◽  
...  
Keyword(s):  
Telomere Length ◽  
Direct Effect ◽  
Indirect Effect ◽  
Mexican Americans ◽  
Mediation Effect ◽  
Model Parameters ◽  
Study Cohort ◽  
C Reactive Protein ◽  
Serum Cotinine ◽  
Reactive Protein

Abstract Background To dissect the direct effect of body mass index (BMI) and its indirect effect through C-reactive protein (CRP) on leukocyte telomere length (LTL) to determine the mediation effect of CRP on the BMI-LTL association. Methods The study cohort included 5,451 adults (1,404 Mexican Americans, 3,114 Whites and 933 Blacks; 53.5% males; mean age=49.2 years) from the 1999-2002 National Health and Nutrition Examination Survey. General mediation models were used to examine the mediation effect of CRP on the BMI-LTL association. Results After adjusting for age, race, sex, physical activity, alcohol use and serum cotinine, the total effect of BMI on LTL was significant (standardized regression coefficient, β= -0.054, p&lt;0.001) without CRP included in the model. With inclusion of CRP in the model, the indirect effect of BMI on LTL through CRP was estimated at β= -0.023 (p&lt;0.001), and the direct effect of BMI on LTL in its absolute value decreased to β= -0.031 (p=0.025). The mediation effect of CRP was estimated at 42.6%. The mediation model parameters did not differ significantly between race and sex groups. Conclusion These results suggest that the inverse BMI-LTL association is partly mediated by obesity-induced inflammation. The significant direct effect of BMI on LTL with removal of the mediation effect through CRP indicates that obesity is associated with LTL attrition also through other non-inflammatory mechanisms.

Sign in / Sign up

Export Citation Format

Share Document